These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 9401831)

  • 1. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):504-8. PubMed ID: 9401831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Eur J Clin Chem Clin Biochem; 1997 Oct; 35(10):775-9. PubMed ID: 9368796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative analysis for crossover studies that accounts for between-group disparities in drug response--corrigenda.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):353. PubMed ID: 9660046
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of alternative statistical models for crossover studies to demonstrate caffeine adjuvancy in the treatment of tension headache.
    Koch GG; Amara IA; MacMillan J
    J Biopharm Stat; 1994 Nov; 4(3):347-410. PubMed ID: 7881452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of extensions of bivariate rank sum statistics to the crossover design to compare two treatments through four sequence groups.
    Kawaguchi A; Koch GG; Ramaswamy R
    Biometrics; 2009 Sep; 65(3):979-88. PubMed ID: 19173698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple analysis of crossover studies with one-group interaction.
    Cleophas TJ
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):322-7. PubMed ID: 7582382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.
    Parienti JJ; Kuss O
    Contemp Clin Trials; 2007 May; 28(3):316-23. PubMed ID: 17110172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal crossover designs for logistic regression models in pharmacodynamics.
    Waterhouse TH; Eccleston JA; Duffull SB
    J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover trials should not be used to test one treatment against another treatment with a totally different chemical class/mode of action.
    Cleophas TJ
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1503-8. PubMed ID: 11185673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative analysis for crossover studies that accounts for between-group disparities in drug response.
    Cleophas TJ
    Clin Chem Lab Med; 1998 Dec; 36(12):981-2. PubMed ID: 9915233
    [No Abstract]   [Full Text] [Related]  

  • 11. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical perspective on adjusting for center effect in a 2 x 2 crossover design with application to clinical trials.
    Yue LQ
    J Biopharm Stat; 2000 Nov; 10(4):559-71. PubMed ID: 11104393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of two-stage test statistic in the two-period crossover trials.
    Wang SJ; Hung HM
    Biometrics; 1997 Sep; 53(3):1081-91. PubMed ID: 9333341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crossover designs in lower extremity wounds.
    Reed JF
    Int J Low Extrem Wounds; 2003 Sep; 2(3):158-63. PubMed ID: 15866840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent.
    Shkedy Z; Molenberghs G; Van Craenendonck H; Steckler T; Bijnens L
    J Biopharm Stat; 2005; 15(2):225-39. PubMed ID: 15796291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of a crossover clinical trial by permutation methods.
    Good P; Xie F
    Contemp Clin Trials; 2008 Jul; 29(4):565-8. PubMed ID: 18356118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CrossOver: an algorithm for the construction of efficient cross-over designs.
    John JA; Russell KG; Whitaker D
    Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The place of the crossover design in infertility trials: a maximum likelihood approach.
    McDonnell J; Goverde AJ; Vermeiden JP
    Hum Reprod; 2004 Nov; 19(11):2537-44. PubMed ID: 15459169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crossover trials with a cumulative response.
    Walter SD
    J Biopharm Stat; 1997 Nov; 7(4):649-66. PubMed ID: 9358336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.